Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — Shareholder Meeting (May 2019)
22 slides from Elixinol Wellness's shareholder meeting presentation, May 23, 2019
Slide 1: AGM, CEO presentation
For personal use only Elixinol Global Limited AGM, CEO presentation 23 May 2019 ASX: EXL, OTCQX: ELLXF | www.elixinolglobal.com
Slide 2: Disclaimer
Disclaimer For personal use only This presentation contains summary information about Elixinol Global Limited (EXL) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with EXL’s other periodic and continuo
Slide 3: Board and management team
Who we Key Growth Outlook Q&A are highlights drivers Board and management team Key market statistics* For personal use only Andrew Duff | Non-Executive Chairman Paul Benhaim1 | CEO / Executive Director Experienced ASX listed company director. Ex CFO Over 25 years’ experience in the hemp of ASX100 co
Slide 4: Corporate overview
Who we Key Growth Outlook Q&A are highlights drivers Corporate overview For personal use only Key market Key statistics 1 market statistics* Share price history ASX: EXL OTCQX: ELLXF • IPO on ASX: 8 January 2018: raised A$20m at price of A$1.00 • September 2018: raised A$40m at price of A$1.85 Share
Slide 5: For personal use only
Who we Key Growth Outlook Q&A are highlights drivers For personal use only Elixinol Global (herein referred to as EXL) is a global consumer brand with products in multiple cannabis verticals, including CBD-based supplements and skincare, hemp food and medical cannabis. 5 EXL | AGM 2019
Slide 6: Diversified portfolio
Who we Key Growth Outlook Q&A are highlights drivers Diversified portfolio FY2018 revenue by business unit For personal use only Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medical Cannabis Revenue $32.5m (87%)* Revenue $4.9m (13%)* Seeking license and permit Submitted license ap
Slide 7: Why we're different
Who we Key Growth Outlook Q&A are highlights drivers Why we’re different For personal use only We believe our products represent the highest quality in the market • Highly diversified business model with multiple products sold through multiple sales channels • In-house R&D efforts focused on develop
Slide 8: FY2018 Key Highlights
Who we Key Growth Outlook Q&A Outlook Q&A Appendix are highlights drivers FY2018 Key Highlights For personal use only Group revenue increased Strong balance sheet with net cash of 121% $42.7m EXL investing to build a to $37.1m driven by continued strong sales by Elixinol to drive international growt
Slide 9: FY2019 Key Highlights
Who we Key Growth Outlook Q&A Outlook Q&A Appendix are highlights drivers FY2019 Key Highlights Strong start with momentum building For personal use only First agreements signed with large European and US retail distributors Strategic investment EU & US National retailer distribution made into Pet R
Slide 10: Elixinol Global key growth initiatives
Who we Key Growth Outlook Q&A Outlook are highlights drivers Elixinol Global key growth initiatives Continued disciplined approach to drive future revenue growth For personal use only 9 Increase distribution through US national retail chains (commenced April 2019) 9 Expansion of operations in Europe
Slide 11: Elixinol Global, international footprint
Who we Key Growth Outlook Q&A Outlook are highlights drivers Elixinol Global, international footprint An established platform that can be leveraged for consumer products For personal use only Global platform for growth • Avenues to market established across • Operations (pins) in: • Expansion plans
Slide 12: Growth Drivers: Elixinol
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Elixinol Firmly positioned to drive revenue growth and take CBD market share For personal use only • Doubling production capacity in the USA with new 12,000 sq. ft. square foot Colorado facility (on track for commissioning
Slide 13: Growth Drivers: Elixinol – US retailer agreements
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Elixinol – US retailer agreements Strong interest from national retailers - first agreements signed and products being stocked For personal use only • Partnered with retail brokerage firm, Presence Marketing – clients contr
Slide 14: Growth Drivers: Elixinol – European retailer agreements
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Elixinol – European retailer agreements Strong interest from national retailers - first agreements signed and products being stocked For personal use only • Recently expanded sales teams in key centres across Europe, includ
Slide 15: Growth Drivers: Elixinol – New York state CBD authorisation
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Elixinol – New York state CBD authorisation Supplying quality product to major national retailers within a clear regulatory framework For personal use only • Elixinol is officially granted a coveted CBD Processor Authorisat
Slide 16: Growth Drivers: Elixinol – Pet Releaf investment
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Elixinol – Pet Releaf investment Strategic investment: 25% equity interest in Altmed Pets, LLC (Pet Releaf)* For personal use only • The most widely distributed hemp and CBD pet product in the market – sold online and throu
Slide 17: Growth Drivers: Hemp Foods Australia
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Hemp Foods Australia Leveraging industry leading position in Australia to further accelerate growth For personal use only • Solidify #1 market position in Australia for hemp food branded • Launched new SATIVA skincare produ
Slide 18: Growth Drivers: Nunyara Pharma (Australia)
Who we Key Growth Outlook Q&A Outlook are highlights drivers Growth Drivers: Nunyara Pharma (Australia) Leveraging US cannabinoid production and formulation expertise for Medical Cannabis For personal use only Subject to ODC licenses and planning approvals: • Cultivate 5000m2 within the 60 acre prop
Slide 19: Outlook
Who we Key Growth Outlook Q&A are highlights drivers Outlook For personal use only EXL’s global investment into top line growth is on track. There is a significant opportunity to grow sales in the US via large national retailers, with ongoing conversations expected to lead to new sales distribution
Slide 20: Strategic outlook: delivering on our corporate strategy
Who we Key Growth Outlook Q&A are highlights drivers Strategic outlook: delivering on our corporate strategy Capturing substantial global growth opportunity in hemp-CBD and medical cannabis For personal use only FY2021 • Global top 3+ leadership FY2020 position in CBD FY2019 consumer products • Glob
Slide 21: Q&A
For personal use only Q&A www.elixinolglobal.com
Slide 22: For more information
For personal use only For more information: Investor relations and media please contact: Australia United States of America Glen Zurcher Cody Slach Account Director, IR Department Managing Director, Gateway Investor Relations IR@elixinolglobal.com | +61 420 249 299 USIR@elixinolglobal.com | +1 949 5